The global Companion Animal Drugs Industry is poised for robust growth, with a projected 4.4% CAGR; reaching US$ 59.2 billion by the conclusion of 2033, up from US$ 36.7 billion in 2022.
Companion animal medications are instrumental in maintaining health and safeguarding pets from infections and other health concerns. Companion animal veterinarians administer these drugs during surgeries to facilitate wound healing, diagnose various ailments, and more.
These medications play a pivotal role in ensuring the well-being of pets while also shielding the entire household caring for them from any potential health risks that the animals may pose. A variety of companion animals, including dogs, cats, horses, and more, routinely benefit from the use of these medications.
Request a Sample Copy of the Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-1077
Increasing Urbanization and Growing Affluence in Developing Countries to Benefit the Market
Increasing urbanization levels and growing affluence, especially in developing countries, have been driving the adoption of pets, thus leading to increased demand for healthcare products for pets such as companion animal drugs. Continued urbanization has also resulted in the increasing prevalence of various diseases such as allergies, lower appetite, reduced energy, and behavioral anxieties among small companion animals. This has been driving the demand for innovative classes of medicines such as companion animal drugs.
Upcoming Therapeutic Innovations in Pet Care to Aid Market Growth
Besides traditional drugs, animal health companies have also been investing in smart diagnostic care to help prevent diseases before their actual onset. Companies are also trying to develop generic capabilities to demonstrate bioequivalence to reference prescription drugs in the companion animal drugs Industry, as many key drugs no longer benefit from intellectual property protection. The development of new vaccines and medications for animals is expected to support the growth of the companion animal drugs Industry over the forecast period.
Increasing R&D activities and shorter drug-lifecycle are playing an important role in the growth of the companion animal drugs Industry. Innovations in companion animal drugs are easier and sustainable for a longer period, while R&D cycle time are shorter (~ three years) in the Companion Animal Healthcare (CAH) industry as compared to human health, ranging between seven and 15 years for other drugs. This increases the return on investment in companion animal drugs and leads to faster profits for the market players.
Grab Your Discount Now Before It is Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-1077
Collaborative Ventures to Promote the Companion Animal Drugs Industry Growth
Collaborative ventures such as One Health promote the unification of veterinary and medical sciences, leading to better disease surveillance, control, and education, especially for companion animals such as dogs and cats. One Health venture enables the identification of alteration in infection traveling patterns. The patterns are changing mostly in the case of parasites due to changes in climate and increasing host-vector interactions. Some organizations helping in monitoring One Health in companion animals are the Companion Animal Parasite Council and European Scientific Counsel Companion Animal Parasites.
Such ventures are expected to complement the growth of the companion animal drugs market.
Low Awareness of Animal Diseases to Hamper the Companion Animal Drugs Industry Growth
In many developing countries, people lack awareness regarding certain serious companion animal diseases as opposed to livestock diseases, which are more regularly monitored. This is primarily true about pet vaccinations, which are a mandatory requirement for up to three years. Additionally, parasitic medications for companion animals and livestock are different. Lack of awareness with regards to the differentiation of these medication varieties leads to adverse drug side effects and thus low administration of companion animal medications. Such factors are likely to create a hindrance in the growth of the companion animal drugs market.
Also, the majority of animal healthcare drugs have limited scope for patent extension, primarily due to drug portfolios dominated by drugs that have crossed maturity, which in turn is expected to deter the growth of the companion animal drugs market over the forecast period.
Key Players in the Companion Animal Drugs Industry:
- Zoetis Inc.
- Merck & Co, Ltd.
- Bayer AG
- Elanco
- Boehringer Ingelheim GmbH (Merial)
- Virbac Animal Health
- Ceva Santè Animale
Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-1077
Key Segments Covered in Companion Animal Drugs Industry Research
Product:
- Antibiotics
- Anti-inflammatory
- Parasiticides
- Heartworm
- Behavioral Products
- Nutritional Products
- Skin Care Products
- Vaccines
Distributional Channel:
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies and Drug Stores
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
